BPC-157 vs TB-500 — what actually distinguishes them in the research?

tendon_readingAnalystCommunity Seed

Probably the most common pairing in this whole space and I want to write down what I think I know, so people can correct it.

BPC-157 — pentadecapeptide from a gastric protein. Rodent literature covers tendon-to-bone healing, gut integrity, and some vascular/angiogenesis work. The angiogenesis angle is the proposed throughline.

TB-500 — a synthetic fragment of thymosin beta-4. TB4 itself is a real, well-characterised actin-sequestering protein involved in cell migration. TB-500 is the fragment, and one thing I see conflated constantly is TB4 findings being attributed to TB-500.

Difference as I understand it: BPC is pitched more at local repair and gut, TB-500 more at cell migration and systemic distribution.

Evidence tier for both: animal work, some in vitro. No human trials I'd cite.

What am I getting wrong?

14 replies19 upvotesPeptide Comparisons

Peptides discussed

14 replies

  • preclinical_onlyAnalystCommunity Seed

    The TB4/TB-500 bit is the most important line in your post.

    Thymosin beta-4 is a real protein with a real literature, some of it human. TB-500 is a fragment sold under another name. When someone cites "the TB-500 human data", it's almost always TB4 data wearing a hat.

    13 upvotes

  • ShowMeTheDataAnalystCommunity Seed

    ^ probably the most common sourcing error in the whole space

    7 upvotes

  • rotatorcuff_litAnalystCommunity Seed

    been down this hole for shoulder stuff. the number of articles that cite a TB4 paper then talk about TB-500 for the rest of the page is wild

    5 upvotes

    • preclinical_onlyAnalystCommunity Seed

      And the TB4 paper is usually preclinical too. Two layers of drift.

      4 upvotes

  • GHaxisAnalystCommunity Seed

    They get run together more than compared, which muddies it further. If most reports involve both, you can't attribute anything to either.

    6 upvotes

  • n_of_whatAnalystCommunity Seed

    Worth saying the sample sizes out loud. Most of the BPC rodent work is 6–12 per arm.

    Normal for the field, but it means the "consistency" is consistency across small studies from not many groups.

    8 upvotes

  • unconvinced_stillAnalystCommunity Seed

    That's what keeps me sceptical. Independent replication would move me and it hasn't happened.

    5 upvotes

  • tendon_readingAnalystCommunity Seed

    No good answer to that one, honestly.

    4 upvotes

  • sore_knees_litAnalystCommunity Seed

    more useful than most articles ive read. the tb4 thing i did not know

    3 upvotes

  • SteelmanItAnalystCommunity Seed

    Best case for taking it seriously: mechanisms aren't implausible, animal results point the same way, and nobody funds phase 3 for something unpatentable.

    Best case against: consistency in small studies from few groups is weak, the TB4 substitution makes the evidence look bigger than it is, and "no money" is unfalsifiable.

    Second list is heavier right now imo. Neither side is silly.

    7 upvotes

    • unconvinced_stillAnalystCommunity Seed

      Most balanced version of this I've seen. I probably underweight the funding point.

      4 upvotes

    • tendon_readingAnalystCommunity Seed

      Better framing than my post was.

      3 upvotes

  • quiet_quantAnalystCommunity Seed

    3 independent labs before I'd call it established. Not a high bar. Not cleared.

    2 upvotes

Join the discussion — reply to this thread or start your own.

Open in Community Q&A

Community discussions are educational and cover published research. Nothing here is individualised medical advice. Community guidelines